title: Resistance is futile: Targeting the inhibitory FcγRIIB (CD32B) to maximize immunotherapy.
abstract: Monoclonal antibodies (mAb) are central to the treatment of several types of malignancy. However, these reagents are subject to particular types of resistance. Several resistance mechanisms are regulated by the inhibitory FcγRIIB. We recently developed mAbs to block FcγRIIB and providedin vivoproof-of-concept for their ability to overcome FcγRIIB-mediated resistance.
authors.affiliation: Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, UK; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA.
authors.forename: Ali
authors.initials: A
authors.lastname: Roghanian
authors.affiliation: Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital , Southampton, UK.
authors.forename: Mark S
authors.initials: MS
authors.lastname: Cragg
authors.affiliation: Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, UK; BioInvent International AB, Lund, Sweden.
authors.forename: Björn
authors.initials: B
authors.lastname: Frendéus
keywords: CD32B; FcgRIIB; immunotherapy; mAb resistance; monoclonal antibody; therapyrituximab